

Bloomberg Intelligence
Bloomberg
Scarlet Fu and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company research. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.
Episodes
Mentioned books

7 snips
Aug 28, 2025 • 22min
Nvidia Forecasts Decelerating Growth After Two-Year AI Boom
Nvidia reveals a cautious revenue forecast, hinting at a slowdown after a two-year AI boom. Retail giants struggle with mixed sales results, with Dollar General adjusting strategies amidst rising costs. Best Buy's long-awaited sales increase faces tariff challenges ahead of the holidays. Meanwhile, Dick's Sporting Goods' acquisition of Foot Locker raises concerns about management's plans for turnaround. The discussion also highlights the resilience of database companies and the potential impact of AI innovations on various sectors.

11 snips
Aug 27, 2025 • 22min
Kohl’s Jumps on Outlook Boost in Sign of Consumer Resilience
In this discussion, Mary Ross Gilbert, a Senior Equity Analyst covering retail, shares insights on Kohl's optimistic sales outlook and strategies for recovery after 14 quarters of decline. Michael Halen, a Senior Restaurant and Food Service Analyst, talks about Cracker Barrel's branding overhaul after a controversial logo change. The conversation also touches on Abercrombie's positive earnings and the broader retail landscape, highlighting adaptability amid economic challenges and changes in consumer behavior.

15 snips
Aug 26, 2025 • 23min
AT&T to Buy EchoStar Spectrum Licenses for About $23 Billion
Sam Fazeli, a pharmaceutical industry expert at Bloomberg Intelligence, discusses Eli Lilly's groundbreaking weight-loss pill, revealing that participants lost an impressive 9.6% of their body weight in trials. Meanwhile, Patricio Alvarez, specializing in Power & Gas Utilities, highlights the regulatory challenges Orsted faces after a construction halt on its offshore wind farm. The conversation also touches on AT&T's $23 billion acquisition of spectrum licenses from EchoStar, exploring its implications for the telecom industry and competition.

6 snips
Aug 25, 2025 • 23min
Keurig Dr Pepper to Buy Peet’s Coffee Owner for $18 Billion in Revamp
Keurig Dr Pepper's bold €15.7 billion acquisition of JDE Peet’s aims to rejuvenate its coffee segment amid declining soda consumption. The challenges of rising coffee prices due to poor crop yields are discussed, along with an increasing trend toward energy drinks. Puma's struggles against competitors like Nike and Adidas are highlighted, alongside a potential sale amid stock value declines. Apple gears up for a significant iPhone redesign, while a broadcasting merger navigates complex regulatory waters.

Aug 22, 2025 • 38min
BI Weekend: Target, Home Depot, Retail Earnings
The podcast dives into the latest earnings from major retailers, revealing consumer trends and economic conditions shaping the future. TJX Companies shows strong performance, with discussion on Target's CEO transition amid mixed results. Estee Lauder faces challenges in luxury demand, while Home Depot pivots towards smaller projects. Insight into Medtronic's impressive earnings and the impact of tariffs on corporate forecasts highlights industry complexities. Also explored are pharmaceutical advancements with Novo Nordisk and sustainable aviation fuel's environmental potential.

10 snips
Aug 22, 2025 • 36min
Instant Reaction: Jay Powell's Jackson Hole Speech
Jim Bullard, the former St. Louis Fed Chief and current Dean at Purdue, and Kate Moore, Chief Investment Officer at Citi Wealth, dive deep into Jay Powell's remarks from Jackson Hole. They discuss potential interest rate cuts and the implications for the labor market amid inflation concerns. Bullard emphasizes the Fed's careful navigation of monetary policy in a changing economic landscape. Moore shares insights on market strategy amidst rising investment optimism and the evolving dynamics of trade—especially around tariffs and their impact on inflation.

Aug 21, 2025 • 18min
Walmart Slumps After Rare Profit Miss Overshadows Higher Sales
Jennifer Bartashus, a Senior Analyst for Retail Staples & Packaged Food at Bloomberg Intelligence, dives into Walmart's surprising profit miss against rising sales. She explores the impact of increased costs like insurance claims and legal charges, and Walmart's strategy to attract higher-income customers. The discussion highlights how tariffs are affecting competition, particularly in contrast to Target. Bartashus also touches on potential investor reactions and Walmart's future positioning in the retail market.

6 snips
Aug 20, 2025 • 23min
Citi Investigated HR Complaints Against Wealth Head Sieg
Citigroup is facing scrutiny as it hires a law firm to investigate HR complaints against its wealth-management chief, Andy Sieg, raising concerns about leadership practices. Meanwhile, Lowe's expands its portfolio with a significant acquisition to enhance its standing in contractor services. TJX's unexpected financial growth highlights how discount retailers are adapting to shifting consumer habits. On the retail front, Target appoints a new CEO to tackle challenges and improve customer experiences during economic uncertainty.

Aug 19, 2025 • 20min
Trump Weighs 10% Government Stake in Intel as Softbank Buys In
Drew Reading, a U.S. Homebuilding Analyst at Bloomberg Intelligence, shares insights on Home Depot's recent rise in sales as customers focus on smaller home projects. He discusses the impacts of rising mortgage rates and changing consumer behaviors in the home improvement market. Additionally, the conversation touches on the challenges facing Intel amid potential government investment and competition with tech giants like TSMC and NVIDIA, highlighting the evolving landscape of the tech and housing sectors.

Aug 18, 2025 • 20min
Novo Halves Ozempic Price to $499 a Month For Those Paying Cash
Lisa Mateo-Madison Muller, a Bloomberg Health Reporter, dives into Novo Nordisk's decision to cut Ozempic's price to $499 monthly for cash payers, highlighting its potential to improve accessibility. She discusses the broader implications for pharmaceutical pricing and patient care. The conversation also touches on Novo’s recent approval of Wegovy for treating serious liver disease and its competitive edge against Eli Lilly’s offerings. Plus, insights into the strategic partnerships formed to enhance access for uninsured individuals add an interesting twist!


